Finanzen von Health Catalyst Inc (HCAT)HCATHealth Catalyst Inc

Health Catalyst, Inc. (HCAT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Recurring technology, accounting for 69.2% of total sales, equivalent to $48.80M. Another important revenue stream is Professional Services. Understanding this composition is critical for investors evaluating how HCAT navigates market cycles within the Software industry.

Evaluating the bottom line, Health Catalyst, Inc. maintains a gross margin of 34.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.35%, while the net margin is -57.51%. These profitability ratios, combined with a Return on Equity (ROE) of -118.12%, provide a clear picture of how effectively HCAT converts its operational activities into shareholder value.

In the context of the broader market, HCAT competes directly with industry leaders such as TRAK and NSTR. With a market capitalization of $112.89M, it holds a significant position in the sector. When comparing efficiency, HCAT's gross margin of 34.64% stands against TRAK's 84.21% and NSTR's N/A. Such benchmarking helps identify whether Health Catalyst, Inc. is trading at a premium or discount relative to its financial performance.

Health Catalyst has experienced a significant decline in revenue and net income, with Q2 2026 net income at -$40.5 million and a gross margin of 34.64%. The forward P/E ratio is 10, but the negative earnings history raises concerns about future profitability.